<DOC>
	<DOCNO>NCT00946972</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacokinetics ( explores body drug ) , pharmacodynamics ( explores drug body ) multiple dose JNJ-38431055 volunteer type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Multiple Doses JNJ-38431055 Volunteers With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This double-blind ( neither physician participant know name assign study drug ) , placebo-controlled ( substance contain medication ) , study male female volunteer type 2 diabetes mellitus . For volunteer , study consist screen phase ( 45 day ) , run-in phase volunteer discontinue oral anti-hyperglycemic drug ( 21 35 day ) , treatment phase volunteer continue anti-hyperglycemic drug receive daily study drug ( JNJ-38431055 placebo ) 14 day , follow-up phase ( 10 day ) . After follow-up phase , volunteer restart oral anti-hyperglycemic drug . The following safety evaluation take throughout study : Electrocardiogram ( ECG painless procedure give picture electrical activity heart ) , blood pressure , heart rate , blood sample laboratory test . The primary outcome safety tolerability JNJ-38431055 24-hour weight mean glucose concentration 14 day dose JNJ-38431055 . Study drug administer daily dos 14 day . The two treatment JNJ-38431055 placebo .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Males postmenopausal surgically sterilize female , type 2 diabetes mellitus Medically stable basis physical examination , medical history , laboratory safety test result , vital sign ECG perform screen Body Mass Index ( BMI ) 22 39.9 kg/m2 , inclusive On generally stable antihyperglycemic agent regimen ( i.e . change medication , 1 dose step change dose ) least 2 month prior Screening visit , include volunteer : ( ) Not currently antihyperglycemic therapy HbA1c &gt; =7.0 % &lt; =10 % , ( b ) On single oral antihyperglycemic agent [ metformin , sunfonylurea , meglitinide ( e.g. , repaglininide nateglinide ) , DPPIV inhibitor ( sitagliptin vildagliptin ) , alphaglucosidase inhibitor ( e.g. , acarbose ) ] HbA1c &gt; =6.5 % &lt; =9.5 % , ( c ) On lowdose dual oral agent therapy ( i.e. , &lt; 50 % maximum labeled dose agent ) HbA1c &gt; =6.5 % &lt; =9.5 % On Day 2 ( two day prior study drug administration ) , FPG concentrations 120 mg/dL 260 mg/dL , inclusive Taking nonoral antihyperglycemic agent ( e.g. , insulin , exenatide GLP1 analogue ) , take thiazolidinedione ( i.e. , PPARg agonist ) within 3 month Screening visit History recent severe hypoglycemic episode , recurrent hypoglycemic episode ( i.e. , within past year ) , history hypoglycemic unawareness History clinically significant diabetic complication , include retinopathy , nephropathy , neuropathy gastroparesis Positive test alcohol and/or drug abuse Psychological and/or emotional problem , would render informed consent invalid , limit ability volunteer comply study requirement Any condition , opinion investigator , would compromise well volunteer study prevent volunteer meeting perform study requirement</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
</DOC>